BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

The FDA’s premarket approval green light spans one pan-cancer ... Finally, the assay can be used with Merck’s Keytruda ...

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... BioNTech is also exploring combinations with antibody-drug ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...